
pmid: 21519217
The treatment of rheumatologic diseases with tumor necrosis factor-alpha antagonists has become common practice. Studies have demonstrated an increased risk of active tuberculosis with use of tumor necrosis factor-alpha antagonists. We aim to better define the risk of tuberculosis infection associated with tumor necrosis factor-alpha antagonists and to review the literature on the treatment of latent tuberculosis.
Adalimumab, Antitubercular Agents, Quebec, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Infliximab, Receptors, Tumor Necrosis Factor, United States, Etanercept, Europe, Latent Tuberculosis, Antirheumatic Agents, Immunoglobulin G, Humans, Mass Screening, Tuberculosis, Immunosuppressive Agents
Adalimumab, Antitubercular Agents, Quebec, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Infliximab, Receptors, Tumor Necrosis Factor, United States, Etanercept, Europe, Latent Tuberculosis, Antirheumatic Agents, Immunoglobulin G, Humans, Mass Screening, Tuberculosis, Immunosuppressive Agents
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 6 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
